Current and emerging therapies for neuroendocrine prostate cancer.

Neuroendocrine prostate cancer is a histological variant of prostate cancer that is characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine markers. Neuroendocrine prostate cancer usually manifests in late-stage prostate cancer patients who have undergone multiple rounds of anti-androgen therapies but can, although rarely, occur in treatment naïve patients de novo. Current therapies to treat neuroendocrine prostate cancer are largely based on their success in treating patients with small cell lung cancer, a lung cancer that shares the neuroendocrine phenotype with neuroendocrine prostate cancer. However, unfortunately these therapies are not durable. In this review, we discuss therapies currently in use to treat neuroendocrine prostate cancer, including platinum-based therapies, taxanes and etoposide. Additionally, we utilize ongoing clinical trials information to identify potential emerging therapies for neuroendocrine prostate cancer. Lastly, we discuss additional potential future opportunities for targeting neuroendocrine prostate cancer.

• Publication year

  2022

• Venue

  Pharmacology and Therapeutics

• Publication date

  2022-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2139/ssrn.4060092PMID 35905791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.

  2022cited by this paper
• Prostate cancer

  2021cited by this paper
• Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

  2021cited by this paper
• A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

  2021cited by this paper
• Prostate cancer

  2021cited by this paper
• Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer.

  2021cited by this paper
• Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.

  2021cited by this paper
• EGFR activation limits the response of liver cancer to lenvatinib

  2021cited by this paper
• Loss and revival of androgen receptor signaling in advanced prostate cancer

  2021cited by this paper
• Clinical and Biological Features of Neuroendocrine Prostate Cancer

  2021cited by this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cited by this paper
• Cancer Statistics, 2021

  2021cited by this paper
• Molecular events in neuroendocrine prostate cancer development

  2021cited by this paper
• Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection

  2021cited by this paper
• Therapy considerations in neuroendocrine prostate cancer: what next?

  2021cited by this paper
• Interleukins in cancer: from biology to therapy

  2021cited by this paper
• Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

  2021cited by this paper
• Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

  2021cited by this paper
• Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients

  2021cited by this paper
• Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

  2021cited by this paper
• Prostate zones and cancer: lost in transition?

  2021cited by this paper
• 523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

  2021cited by this paper
• The contribution of PARP1, PARP2 and poly(ADP-ribosyl)ation to base excision repair in the nucleosomal context

  2020cited by this paper
• Re: Selective Targeting of PARP-2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth through Disruption of FOXA1 Function.

  2020cited by this paper
• The rediscovery of platinum-based cancer therapy

  2020cited by this paper
• Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.

  2020cited by this paper
• Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer

  2020cited by this paper
• Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

  2020cited by this paper
• Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).

  2020cited by this paper
• Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature

  2020cited by this paper
• Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma

  2020cited by this paper
• Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

  2020cited by this paper
• Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report

  2020cited by this paper
• Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours

  2020cited by this paper
• Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

  2020cited by this paper
• The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo

  2020cited by this paper
• Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression

  2020cited by this paper
• Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1

  2020cited by this paper
• Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

  2020cited by this paper
• Dual inhibitors of human DNA topoisomerase II and other cancer-related targets.

  2020cited by this paper
• Neuroendocrine and Aggressive-Variant Prostate Cancer

  2020cited by this paper
• AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

  2020cited by this paper
• Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.

  2020cited by this paper
• Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

  2019cited by this paper
• The role of interleukin-1 in general pathology

  2019cited by this paper
• Epidemiology of Prostate Cancer

  2019cited by this paper
• An innate interaction between IL-18 and the propeptide that inactivates its precursor form

  2019cited by this paper
• PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer

  2019cited by this paper
• Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer

  2019cited by this paper
• Apalutamide: A new agent in the management of prostate cancer

  2019cited by this paper
• Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death.

  2019cited by this paper
• Biological Evolution of Castration-resistant Prostate Cancer.

  2019cited by this paper
• Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer

  2019cited by this paper
• N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

  2019cited by this paper
• Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

  2019cited by this paper
• Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

  2019cited by this paper
• Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function

  2019cited by this paper
• Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines

  2019cited by this paper
• Clinical features of neuroendocrine prostate cancer.

  2019cited by this paper
• Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer

  2018cited by this paper
• Clinical and molecular features of treatment‐related neuroendocrine prostate cancer

  2018cited by this paper
• Neuroendocrine tumors of the prostate

  2018cited by this paper
• Targeting VEGF/VEGFR to Modulate Antitumor Immunity

  2018cited by this paper
• Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date

  2018cited by this paper
• Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

  2018cited by this paper
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

  2018cited by this paper
• Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

  2018cited by this paper
• Genetics and biology of prostate cancer

  2018cited by this paper
• Role of Androgen Receptor in Prostate Cancer: A Review

  2018cited by this paper
• Localized Prostate Cancer: Treatment Options.

  2018cited by this paper
• Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer

  2018cited by this paper
• Enzalutamide: A Review in Castration-Resistant Prostate Cancer

  2018cited by this paper
• Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

  2018cited by this paper
• Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

  2017cited by this paper
• Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells

  2017cited by this paper
• Mechanisms of Therapeutic Resistance in Prostate Cancer

  2017cited by this paper
• Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications

  2017cited by this paper
• Emerging Variants of Castration-Resistant Prostate Cancer

  2017cited by this paper
• The ETS family of oncogenic transcription factors in solid tumours

  2017cited by this paper
• Prostate cancer: N-Myc expression drives neuroendocrine disease

  2016cited by this paper
• The oncogene ERG: a key factor in prostate cancer

  2016cited by this paper
• N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

  2016cited by this paper
• N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

  2016cited by this paper
• Divergent clonal evolution of castration resistant neuroendocrine prostate cancer

  2016cited by this paper
• Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

  2015cited by this paper
• Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure

  2015cited by this paper
• Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives

  2015cited by this paper
• Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

  2014cited by this paper
• Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.

  2014cited by this paper
• Cytoskeleton targeting value in prostate cancer treatment.

  2014cited by this paper
• Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

  2014cited by this paper
• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

  2013cited by this paper
• Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  2013cited by this paper
• Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer

  2013cited by this paper
• Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer

  2012cited by this paper
• ARN-509: a novel antiandrogen for prostate cancer treatment.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• ERG gene rearrangements are common in prostatic small cell carcinomas

  2011cited by this paper
• AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

  2011cited by this paper
• ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin

  2011cited by this paper

• Dictamnine Inhibits WNT Pathway and EMT Progression in Prostate Cancer and Remodels the Tumor Microenvironment

  2026cites this paper
• Integrative multi-omics analysis reveals metabolic dysfunction signatures as critical determinants of prostate cancer prognosis and immunosuppressive microenvironments.

  2026cites this paper
• Targeting Metal Ion Homeostasis for Regulated Cell Death-Amplified Tumor Nanomedicine

  2025cites this paper
• Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

  2025cites this paper
• Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance

  2025cites this paper
• Lanatoside C Inhibits Proliferation and Induces Apoptosis in Human Prostate Cancer Cells Through the TNF/IL-17 Signaling Pathway

  2025cites this paper
• Comparative Analysis of 3D Culture Methodologies in Prostate Cancer Cells

  2025cites this paper
• Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide

  2025cites this paper
• A prognostic model for highly aggressive prostate cancer using interpretable machine learning techniques

  2025cites this paper
• Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer

  2025cites this paper
• New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic

  2025cites this paper
• Comparative Analysis of 3D Culture Methodologies in Prostate Cancer Cells.

  2025cites this paper
• New frontiers in prostate cancer treatment from systemic therapy to targeted therapy

  2025cites this paper
• Nonbone Metastasis in Prostate Cancer: Characteristics, Tumor Microenvironment, Diagnosis and Treatment

  2025cites this paper
• Koningic acid reduces tumor activity in neuroendocrine prostate cancer by inhibiting glycolysis.

  2025cites this paper
• The molecular aspects in prostatic cancer, unraveling the role of CDKs in prostate cancer progression

  2025cites this paper
• LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer

  2025cites this paper
• Extracellular vesicles-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells.

  2025cites this paper
• The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.

  2024cites this paper
• Neuroendocrine Prostate Cancer: Report of a Prostate Cancer Subtype with Atypical Metastatic Imaging and Clinical Findings

  2024cites this paper
• Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer

  2024cites this paper
• The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers

  2024cites this paper
• Structural Optimization of Isoquinoline Derivatives from Lycobetaine and Their Inhibitory Activity against Neuroendocrine Prostate Cancer Cells

  2024influential citation
• Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells

  2024cites this paper
• Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

  2024cites this paper
• Proteomic Analysis of Microsomal Proteins Reveals That MVP Is Crucial for the Secretion of GDF-15, Which in Turn Promotes the Neuroendocrine Differentiation of PCa Cells.

  2024cites this paper
• Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask

  2024cites this paper
• PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

  2024cites this paper
• Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer.

  2024cites this paper
• Das metastasierte Prostatakarzinom: Therapieoptionen

  2024cites this paper
• Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

  2024cites this paper
• Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.

  2024cites this paper
• Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach

  2024cites this paper
• UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

  2024cites this paper
• Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA: A Case Report.

  2024cites this paper
• Lethal disseminated intravascular coagulation induced by primary and metastatic neuroendocrine prostate cancer

  2024cites this paper
• A Review of the Evolving Role of Radiotherapy in the Treatment of Neuroendocrine Neoplasms

  2024cites this paper
• Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer

  2024cites this paper
• MTHFD2 in healthy and cancer cells: Canonical and non-canonical functions

  2024cites this paper
• The Current Therapeutic Landscape for Metastatic Prostate Cancer

  2024cites this paper
• Cell Membrane‐Camouflaged Chitosan‐Polypyrrole Nanogels Co‐Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer

  2024cites this paper
• Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

  2024cites this paper
• From biology to the clinic — exploring liver metastasis in prostate cancer

  2024cites this paper
• Assessment of Anti-Prostate Cancer Activity among Four Seaweeds, with Focus on Caulerpa lentillifera J.Agardh

  2024cites this paper
• Unveiling the latest insights into Androgen Receptors in Prostate Cancer

  2024influential citation
• Prognostic nomogram to predict cancer-specific survival with small-cell carcinoma of the prostate: a multi-institutional study

  2024cites this paper
• Understanding the molecular regulators of neuroendocrine prostate cancer.

  2024cites this paper
• Synergistic combination therapy with ONC201 or ONC206, Enzalutamide and Darolutamide in preclinical studies of castration-resistant prostate cancer

  2024cites this paper
• The β-Secretase 1 Enzyme as a Novel Therapeutic Target for Prostate Cancer

  2023cites this paper
• Dual-source powered nanomotors coupled with dual-targeting ligands for efficient capture and detection of CTCs in whole blood and in vivo tumor imaging.

  2023cites this paper
• Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate

  2023cites this paper
• Advances in bio-immunotherapy for castration-resistant prostate cancer

  2023cites this paper
• Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity.

  2023cites this paper
• Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer’s Impediments: Current Understanding and Therapeutic Implications

  2022cites this paper